In oncology, benzotriazole derivatives are effective as protein tyrosine kinase (PTK) inhibitors, competing with ATP for the adenine-binding region of PTKs, thereby inhibiting cancer cell growth by blocking phosphorylation signal transduction and abnormal PTK expression. Here, PTK2B is linked to cancer.